Where triple-negative breast cancer treatment is heading
Triple-negative breast cancer · Updated Nov 15, 2026
Triple-negative breast cancer (TNBC) makes up about 1 in 7 breast cancers. It lacks the three receptors that hormone and HER2 drugs target, so chemotherapy, immunotherapy and antibody-drug conjugates (antibodies that carry chemotherapy into cancer cells) are the main tools. Early TNBC is treated with chemotherapy plus pembrolizumab before and after surgery. In 2025 and 2026, TROP2 antibody-drug conjugates beat chemotherapy as first treatment for advanced disease, and trials are now testing them after surgery.
- 590studies open or running
- 72phase 3 trials
- 3,750papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Antibody-drug conjugates move to first lineHappened 11.2 months without progression
Sacituzumab govitecan plus pembrolizumab (11.2 vs 7.8 months) and Dato-DXd (23.7 vs 18.7 months survival) beat chemotherapy-based first treatment.
11.2: months without progression, vs 7.8 with chemo plus pembrolizumab.
Pembrolizumab around surgery saves livesHappened 86.6% alive at 5 years
Final KEYNOTE-522 results: 86.6% alive at 5 years vs 81.7%. A trial of atezolizumab instead did not clearly help.
86.6%: alive at 5 years, vs 81.7% without pembrolizumab.
Olaparib for inherited BRCA mutationsHappened 89.8% alive at 4 years
A year of olaparib after treatment raised 4-year survival to 89.8% vs 86.4%.
89.8%: alive at 4 years, vs 86.4% with placebo.
-
6 months
by May 2027
Pembrolizumab for leftover cancerLikely
SWOG S1418 (1,195 people) tests a year of pembrolizumab after surgery when cancer remained; its main analysis was due August 2026.
Sacituzumab govitecan after surgeryPossible 9.7 months without progression (advanced)
GBG's SASCIA (1,332 people) compares it with standard chemotherapy for leftover cancer; due March 2027.
9.7: months without progression in advanced disease, vs 6.9 with chemotherapy.
-
12 months
by Nov 2027
Antibody-drug conjugates after surgeryPossible
ASCENT-05 (Gilead, due June 2027) and TROPION-Breast03 (AstraZeneca, due September 2027) test them for cancer left after pre-surgery treatment.
Dato-DXd with immunotherapy firstPossible 23.7 months median survival (Dato-DXd alone)
TROPION-Breast05 (625 people) tests Dato-DXd with durvalumab for PD-L1-positive advanced TNBC; due July 2027.
23.7: months median survival with Dato-DXd alone, vs 18.7.
-
3 years
by late 2029
A new pre-surgery regimenPossible
TROPION-Breast04 (1,902 people) compares Dato-DXd plus durvalumab with the KEYNOTE-522 regimen; due November 2028. A win could reduce chemotherapy before surgery.
An EGFR-HER3 antibody-drug conjugatePossible
Bristol Myers Squibb's trial (600 people) compares iza-bren with chemotherapy in previously treated TNBC; due March 2028.
-
5 years
by late 2031
PD-L1 and VEGF bispecificsLong shot 73.8% tumors shrank (early trial)
BioNTech's ROSETTA Breast-01 (558 people) tests pumitamig with chemotherapy; due December 2029.
73.8%: of tumors shrank in an early trial.
Sac-TMT across stagesPossible 6.7 months without progression (later line)
Merck's trials test sac-TMT first line (due May 2030) and after surgery with pembrolizumab (due December 2030).
6.7: months without progression with sac-TMT, vs 2.5 with chemotherapy.
The research paths
TROP2 antibody-drug conjugates
11.2 months without progressionDetails and 7 trialsHide
Sacituzumab govitecan, Dato-DXd and sac-TMT carry chemotherapy into cancer cells. After winning in advanced disease, they are now tested before and after surgery.
WatchASCENT-05; TROPION-Breast03; TROPION-Breast04.
- ASCENT-04 trial (sacituzumab govitecan plus pembrolizumab)
- TROPION-Breast02 trial (Dato-DXd)
- OptiTROP-Breast01 trial (sac-TMT)
- Sacituzumab govitecan plus pembrolizumab after surgery (ASCENT-05)Gilead Sciences · 1,514 people · enrolling Jun 2027
- Dato-DXd with or without durvalumab after surgery (TROPION-Breast03)AstraZeneca · 1,174 people · fully enrolled Sep 2027
- Dato-DXd with or without durvalumab, first line (TROPION-Breast05)AstraZeneca · 625 people · enrolling Jul 2027
- Dato-DXd plus durvalumab before surgery (TROPION-Breast04)AstraZeneca · 1,902 people · fully enrolled Nov 2028
- Sac-TMT plus pembrolizumab after surgeryMerck · 1,530 people · enrolling Dec 2030
- Sac-TMT, first lineMerck · 1,000 people · enrolling May 2030
- Sacituzumab govitecan after surgery (SASCIA)GBG · 1,332 people · fully enrolled Mar 2027
Fine-tuning immunotherapy
86.6% alive at 5 yearsDetails and 3 trialsHide
Who needs a full year of pembrolizumab, who can skip anthracyclines, and how to help people with cancer left after surgery.
WatchSWOG S1418; OptimICE-pCR; SWOG S2212.
- Pembrolizumab after surgery for residual cancer (SWOG S1418)National Cancer Institute · 1,195 people · fully enrolled Aug 2026
- Pembrolizumab vs observation after complete response (OptimICE-pCR)Alliance · 1,295 people · enrolling May 2033
- Shorter chemo-immunotherapy without anthracyclines (SWOG S2212)SWOG · 2,400 people · enrolling Mar 2033
New targets and bispecifics
73.8% tumors shrankDetails and 2 trialsHide
Antibodies that block PD-L1 and VEGF together, and conjugates aimed at EGFR and HER3.
WatchROSETTA Breast-01.
Borrowed from other cancers
From Lung cancer
Pumitamig
Phase 3
A PD-L1 and VEGF bispecific antibody also in phase 3 for small cell and non-small cell lung cancer.
From EGFR-mutant lung cancer
Izalontamab brengitecan
Phase 3
An EGFR-HER3 antibody-drug conjugate first developed in lung and esophageal cancer.
From Ovarian cancer
Olaparib
Approved
A PARP inhibitor first approved for BRCA-mutated ovarian cancer, now used after treatment for BRCA-mutated breast cancer.
Open to join now
-
Cancer left after pre-surgery treatment
Sacituzumab govitecan plus pembrolizumab
Locations and eligibility → -
Cancer left after pre-surgery treatment
Sac-TMT plus pembrolizumab
Locations and eligibility → -
Advanced, PD-L1-positive, first treatment
Dato-DXd with or without durvalumab
Locations and eligibility → -
Advanced, first treatment
Pumitamig plus chemotherapy
Locations and eligibility → -
Early-stage TNBC
Shorter treatment without anthracyclines
Locations and eligibility →
See every recruiting TNBC trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Pumitamig plus chemo shrinks most tumors in early trial
Lancet Oncology.
Atezolizumab before surgery misses main goal
NSABP B-59/GeparDouze, Nature Medicine.
Dato-DXd extends survival in first-line TNBC
TROPION-Breast02, Annals of Oncology.
Sacituzumab govitecan plus pembrolizumab beats chemo plus pembrolizumab
ASCENT-04, NEJM.
Standard treatment today
- Stage I (small tumors)Surgery and chemotherapy; tumors under about 1 cm may need less.
- Stage II and IIIChemotherapy plus pembrolizumab before surgery, then pembrolizumab after (KEYNOTE-522).
- Cancer left after pre-surgery treatmentCapecitabine, or olaparib if an inherited BRCA mutation, alongside pembrolizumab.
- Advanced, first treatmentChemotherapy plus pembrolizumab if PD-L1-positive; antibody-drug conjugates increasingly used.
- Advanced, later treatmentSacituzumab govitecan, trastuzumab deruxtecan for HER2-low tumors, or a PARP inhibitor for BRCA mutations.
How to read this page, and sourcesHow to read this page, and sources
- Some TNBC tumors are HER2-low, which opens other drugs such as trastuzumab deruxtecan; ask about HER2-low testing.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See TNBC trials recruiting now →